In 2013, a drug arrived that did something no oral diabetes medication had ever done before: it lowered blood sugar not by touching the pancreas or improving insulin sensitivity, but by making your kidneys dump glucose directly into your urine. That drug was canagliflozin — Invokana. Within a decade, the SGLT2 class had proven it could reduce cardiovascular death, cut heart failure hospitalizations in half, and slow the progression of chronic kidney disease. They are now prescribed to patients who don’t even have diabetes.
SGLT2 stands for sodium-glucose cotransporter 2 — a protein that lives in the proximal tubule of your kidney and is responsible for reabsorbing roughly 90% of the glucose that gets filtered out of your blood. Under normal circumstances, almost no glucose makes it into your urine. SGLT2 inhibitors block that reabsorption. The result: your kidneys start excreting 60–90 grams of glucose per day directly into your urine.
That caloric loss — roughly 240–360 calories per day — drives modest but consistent weight loss. The glucose excretion also pulls water and sodium along with it (osmotic diuresis), which lowers blood pressure and reduces fluid volume. That fluid-reducing effect turns out to be exactly what the failing heart needs, which is why the cardiovascular and heart failure benefits emerged from trials that were originally designed just to show glucose lowering.
Jardiance, developed by Boehringer Ingelheim and Eli Lilly, was FDA-approved in August 2014 for Type 2 diabetes. It became the defining drug of the class after the EMPA-REG OUTCOME trial (2015) shocked the cardiology world: empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35% in T2D patients with established CV disease. These were not surrogate endpoints — they were deaths prevented. The trial results were presented at the European Society of Cardiology congress and described by attendees as among the most important cardiovascular data in a generation.
Jardiance received expanded FDA approval for heart failure with reduced ejection fraction (HFrEF) in 2021, and for heart failure with preserved ejection fraction (HFpEF) in 2022 — becoming one of the first medications proven effective in HFpEF, a condition that had resisted every prior drug tested. Approval for chronic kidney disease (CKD) followed in 2023 based on EMPA-KIDNEY trial data.
Standard dosing: 10mg daily; may increase to 25mg for additional CV/renal benefit.
Farxiga, developed by AstraZeneca, was FDA-approved in January 2014 — the first SGLT2 to market, by two months over Jardiance. The DECLARE-TIMI 58 trial (2018) showed dapagliflozin significantly reduced heart failure hospitalizations and renal progression events, though it did not achieve the dramatic CV mortality reduction seen with empagliflozin — likely due to trial design differences (DECLARE enrolled lower-risk patients).
Dapagliflozin broke new ground with DAPA-HF (2019) and DAPA-CKD (2020). DAPA-HF showed a 26% reduction in worsening heart failure or CV death — and nearly half the patients enrolled did not have diabetes. DAPA-CKD showed a 39% reduction in CKD progression or death — again, in a population that included non-diabetic patients. These trials established SGLT2 inhibitors as a disease-modifying therapy for heart and kidney disease, not just a diabetes drug.
Standard dosing: 10mg daily for T2D and heart failure; 10mg for CKD.
Invokana, developed by Janssen (J&J), was the first SGLT2 inhibitor approved by the FDA — March 2013. The CANVAS program (2017) showed a 14% reduction in MACE but also revealed a troubling signal: a doubling of the risk of lower-limb amputations, primarily at the toe or foot level. The FDA added a black box warning in May 2017. Subsequent analyses suggested the amputation risk may be related to pre-existing peripheral vascular disease or neuropathy rather than being a class effect — Jardiance and Farxiga have not shown the same signal — but it significantly dampened Invokana’s prescribing momentum.
The CREDENCE trial (2019) showed canagliflozin reduced the risk of kidney failure, dialysis, transplant, or renal death by 30% in T2D patients with diabetic kidney disease. Invokana now carries an indication for reducing CKD progression in T2D. Standard dosing: 100mg daily; may increase to 300mg.
| Trial | Drug | Key Finding | Year |
|---|---|---|---|
| EMPA-REG OUTCOME | Empagliflozin | −38% CV death; −35% HF hospitalization | 2015 |
| CANVAS | Canagliflozin | −14% MACE; +2× amputation risk | 2017 |
| DECLARE-TIMI 58 | Dapagliflozin | −27% HF hospitalization; neutral MACE | 2018 |
| CREDENCE | Canagliflozin | −30% kidney failure / renal death | 2019 |
| DAPA-HF | Dapagliflozin | −26% HF worsening or CV death (incl. non-diabetics) | 2019 |
| DAPA-CKD | Dapagliflozin | −39% CKD progression or death (incl. non-diabetics) | 2020 |
| EMPA-KIDNEY | Empagliflozin | −28% kidney disease progression or CV death | 2023 |
SGLT2 inhibitors are not the most powerful glucose-lowering agents in the T2D toolkit. That’s not their primary value now. HbA1c reductions average 0.5–1.0% at standard doses — meaningful but modest compared to GLP-1s or sulfonylureas. Weight loss averages 2–3 kg (4–7 lbs) over 6 months. Systolic blood pressure drops 3–5 mmHg. Their value is in the organ protection — heart, kidney, and liver — that goes beyond any glucose number.
Genital mycotic infections — The most common side effect. Glucose in the urine creates an environment that yeast thrives in. Vaginal yeast infections affect approximately 10–15% of women on SGLT2s. Balanitis (penile yeast infection) affects 4–6% of men. These are typically mild and treatable with standard antifungal therapy, but they recur as long as the medication continues. Good genital hygiene reduces frequency.
Urinary tract infections — Slightly increased risk, particularly in women. Glucosuria provides a substrate for bacterial growth. Most are uncomplicated lower UTIs. Pyelonephritis (kidney infection) is rare but more serious if it occurs.
Dehydration and hypotension — Osmotic diuresis removes fluid. In elderly patients or those on diuretics, this can cause symptomatic low blood pressure, dizziness, and falls. Fluid intake should increase when starting an SGLT2. Dose reduction or discontinuation of concurrent diuretics may be warranted.
Euglycemic diabetic ketoacidosis (DKA) — A serious, underappreciated risk. Normally DKA is associated with very high blood glucose. SGLT2s can trigger DKA even when blood glucose is near-normal (euglycemic DKA) — because the drug masks the glucose elevation while ketone production continues. This means patients and clinicians may not recognize the crisis until it’s advanced. Risk is highest during: prolonged fasting, very low-carbohydrate diets, illness, surgery, excessive alcohol, and in patients who have some Type 1 features (LADA). SGLT2s must be held 3–4 days before elective surgery.
Fournier’s gangrene — Rare but devastating. A necrotizing fasciitis (flesh-eating infection) of the genitalia and perineum. The FDA added a warning in August 2018 after reviewing 12 cases in SGLT2 users between 2013–2018. Seven of those patients required surgical débridement; one died. The absolute risk is extremely low, but the condition is life-threatening when it occurs. Seek immediate medical attention for any pain, tenderness, redness, or swelling in the genital or perineal area.
Lower-limb amputations — Observed specifically with canagliflozin (Invokana) in the CANVAS program: approximately 6.3 amputations per 1,000 patient-years vs. 3.4 in the placebo group. The FDA black box warning was added in 2017. The mechanism is unclear but may relate to volume depletion reducing peripheral perfusion in patients with pre-existing peripheral artery disease. This signal has not been replicated with empagliflozin or dapagliflozin in their large trials.
Bone fractures — Again specific to canagliflozin: the CANVAS program showed increased fracture risk at 4 weeks of use — a timeframe suggesting a fall risk from postural hypotension rather than a bone density effect. An FDA warning was added. Other SGLT2s have not shown a consistent fracture signal.
Lower-limb amputation black box — Invokana, 2017. Based on CANVAS data. This was the first black box warning ever added to a diabetes drug for an outcome unrelated to cardiovascular disease. It had an immediate negative impact on canagliflozin prescribing and largely handed market leadership to Jardiance and Farxiga.
Fournier’s gangrene — class-wide, 2018. The FDA extended this warning to all SGLT2 inhibitors, not just canagliflozin, based on the post-market case series.
Euglycemic DKA — class-wide, 2015. The FDA issued a drug safety communication in May 2015 warning that SGLT2 inhibitors can cause DKA with blood glucose levels that are only minimally elevated. This was a significant surprise — the drug class was assumed safe from DKA because its mechanism doesn’t involve insulin. The warning revised surgical and fasting protocols across the country.
Acute kidney injury — class-wide, 2016. Post-market reports of acute kidney injury, some requiring hospitalization or dialysis, prompted an FDA warning in June 2016. This appears related to volume depletion — ensure adequate hydration, especially during illness.
SGLT2 inhibitors have now been used widely for a decade. The long-term picture is genuinely positive — unusual for a drug class. The CV and renal protection appears to be durable. The EMPA-REG extension data shows sustained benefit at 4+ years. There is no evidence of drug tolerance or diminishing efficacy over time for organ protection, even if the glucose-lowering effect may modestly attenuate.
The 2023 American Diabetes Association guidelines made a significant shift: they now recommend SGLT2 inhibitors or GLP-1 agonists as preferred second agents after metformin in patients with established cardiovascular disease, heart failure, or CKD — regardless of HbA1c level. This is a paradigm change. These drugs are no longer just glucose-lowering agents; they are organ-protective therapies that happen to lower glucose.
For patients with heart failure or CKD, nephrologists and cardiologists now frequently prescribe SGLT2s independently — without endocrinologist involvement — because the indication no longer requires diabetes. This has expanded the patient population on SGLT2s well beyond the T2D community.
Please understand that I’m not a doctor, and everything on this site reflects my own research and personal experience managing Type 2 diabetes. It is provided for informational and educational purposes only — not as medical advice, diagnosis, or treatment.
Before starting any supplement, changing your diet, or adjusting your medications, consult your physician or a qualified healthcare provider. Individual results vary. Never delay or disregard professional medical advice because of something you read here.
Product photos and brand names appear for illustrative purposes only. Denyabetic does not endorse, sponsor, or have any commercial relationship with any brand shown unless explicitly stated.
These statements have not been evaluated by the Food and Drug Administration. No product or protocol discussed on this site is intended to diagnose, treat, cure, or prevent any disease.